Analyst Reco. Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 12/06/2024 pm IST			5-day change	1st Jan Change
1,847 ^DKK	-2.48%		-4.67%	-14.29%

10/06	Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
04/06	Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	04/06	MT
GENMAB : A good start to 2024; guidance unchanged	03/05
GENMAB : Genmab is available at a bargain price	04/03
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46	23/02	MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating	21/02	MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks	15/02
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating	29/01	MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating	09/11	MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating	08/11	MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded	08/11
GENMAB : Factoring in some caution	31/23/31
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating	13/23/13	MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact	25/23/25
BTIG Starts Genmab at Buy With $44 Price Target	24/23/24	MT
GENMAB : A good Q2 + improved sales guidance	04/23/04
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate	28/23/28	MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma	09/23/09	MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating	22/23/22	MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	16/23/16	MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss	11/23/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 10:38 pm IST